Abstract
Mild mitochondrial uncoupling, or the reduction of the efficiency of energy conversion without compromising intracellular high energy phosphate levels, is a protective therapeutic strategy under many laboratory conditions. Here we discuss these conditions, which include both cell and animal models of ischemia reperfusion and complications associated with the metabolic syndrome. We also discuss drugs that promote mild mitochondrial uncoupling and naturally occurring mild mitochondrial uncoupling pathways involving free fatty acid cycling and K+ transport.
Keywords: Mitochondria, uncoupler, dinitrophenol, uncoupling protein, adenine nucleotide translocator, ATP-sensitive K+ channels, redox sensitive pathways, ROS release, energy metabolism, flavoenzymes
Current Drug Targets
Title: Mild Mitochondrial Uncoupling as a Therapeutic Strategy
Volume: 12 Issue: 6
Author(s): Fernanda M. Cunha, Camille C. Caldeira da Silva, Fernanda M. Cerqueira and Alicia J. Kowaltowski
Affiliation:
Keywords: Mitochondria, uncoupler, dinitrophenol, uncoupling protein, adenine nucleotide translocator, ATP-sensitive K+ channels, redox sensitive pathways, ROS release, energy metabolism, flavoenzymes
Abstract: Mild mitochondrial uncoupling, or the reduction of the efficiency of energy conversion without compromising intracellular high energy phosphate levels, is a protective therapeutic strategy under many laboratory conditions. Here we discuss these conditions, which include both cell and animal models of ischemia reperfusion and complications associated with the metabolic syndrome. We also discuss drugs that promote mild mitochondrial uncoupling and naturally occurring mild mitochondrial uncoupling pathways involving free fatty acid cycling and K+ transport.
Export Options
About this article
Cite this article as:
M. Cunha Fernanda, C. Caldeira da Silva Camille, M. Cerqueira Fernanda and J. Kowaltowski Alicia, Mild Mitochondrial Uncoupling as a Therapeutic Strategy, Current Drug Targets 2011; 12 (6) . https://dx.doi.org/10.2174/138945011795528778
DOI https://dx.doi.org/10.2174/138945011795528778 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue
CNS & Neurological Disorders - Drug Targets Thymoquinone Shows the Diverse Therapeutic Actions by Modulating Multiple Cell Signaling Pathways: Single Drug for Multiple Targets
Current Pharmaceutical Biotechnology Nasal Delivery of Antioxidants by Cholesterol-incorporated Liposomes Extends the Neuroprotective Time Window in Cerebral Ischemia
Current Pharmaceutical Design Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets 4-Methylumbelliferones Analogues as Anticancer Agents: Synthesis and in Cell Pharmacological Studies
Anti-Cancer Agents in Medicinal Chemistry Iptakalim Hydrochloride and Neuronal Protection
Current Neuropharmacology The Role of Autophagy in Subarachnoid Hemorrhage: An Update
Current Neuropharmacology The Impact of Asymmetric Dimethylarginine (ADAMA), the Endogenous Nitric Oxide (NO) Synthase Inhibitor, to the Pathogenesis of Gastric Mucosal Damage
Current Pharmaceutical Design The Application of Angiotensin Converting Enzyme Inhibitors in Heart Surgery
Letters in Drug Design & Discovery Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Redox Homeostasis, Bioactive Agents and Transduction Therapy
Current Signal Transduction Therapy Exosomes and Exosomal microRNAs in Age-associated Stroke
Current Vascular Pharmacology Curcumin: Not So Spicy After All
Mini-Reviews in Medicinal Chemistry Use of Clinically Available PPAR Agonists for Heart Failure; Do the Risks Outweigh the Potential Benefits?
Current Molecular Pharmacology Angiopoietin-1 and C16 Peptide Attenuate Vascular and Inflammatory Responses in Experimental Allergic Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Anti-Inflammatory Iridoids of Botanical Origin
Current Medicinal Chemistry Natural Antioxidants: Therapeutic Prospects for Cancer and Neurological Diseases
Mini-Reviews in Medicinal Chemistry The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Current Drug Targets Functional Genomics of Cardioprotection by Ischemic Conditioning and the Influence of Comorbid Conditions: Implications in Target Identification
Current Drug Targets